Baduanjin Lowers Systolic BP by 5 mm Hg, Matching Drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Baduanjin participants lowered 24‑hour systolic blood pressure by ~3 mm Hg after three months and one year, compared with self‑directed exercise.
- Baduanjin also reduced office systolic blood pressure by 5 mm Hg over the same periods, a magnitude comparable to first‑line antihypertensive medication.
- Jing Li (MD, PhD) led the study as senior author and director of preventive medicine at the National Center for Cardiovascular Diseases in Beijing, noting the routine’s simplicity and safety for long‑term adherence.
- Harlan M. Krumholz (MD, FACC), editor‑in‑chief of JACC, highlighted that the effect size matches that of landmark drug trials but without medication cost or side effects.
- The trial enrolled 216 adults aged ≥40 with stage 1 hypertension (systolic 130‑139 mm Hg) across seven community sites and assigned them to baduanjin, self‑directed exercise, or brisk walking for one year.
- Self‑directed exercise was the control group, and the study found that baduanjin’s blood‑pressure reductions were similar to those achieved by brisk walking after one year.
- The American College of Cardiology disseminated the findings in JACC, emphasizing the potential for baduanjin to serve as an accessible, low‑cost lifestyle intervention for community‑based prevention, especially in resource‑limited settings.
Why it matters: Patients with stage 1 hypertension gain a low‑cost, medication‑free option for blood‑pressure control, while healthcare systems could reduce drug expenditures and improve adherence; the finding also validates ancient mind‑body practices for modern preventive medicine and offers a scalable solution for community health programs, especially where access to gyms or medication is limited.
